94 reports

  • OF CONTENTS

In December 2017, the FDA approved Bristol-Myers Squibb' s PD-## inhibitor Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

  • Hepatitis
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

Journal of Global Infectious Diseases; ##(##): ##- ##.

  • Hepatitis
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • Commitment to innovation in technology Availability of affordable and high-quality medicines
  • OTHER PROMINENT VENDORS

About hepatitis Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases....

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • FINANCIAL

EACH PARTY, THROUGH ITS REPRESENTATIVES, SHALL HAVE ONE (##) VOTE ON THE JSC AND EACH SUBCOMMITTEE.

  • Hepatitis
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC

(USA) ##.

  • Antiviral
  • Hepatitis
  • United States
  • World
  • Market Shares

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.

IFN-based therapies such as Pegintron have adverse side effects and are not recommended for use in patients with advanced liver diseases or autoimmune disorders.

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • GLOBAL ANTIVIRAL DRUGS MARKET SEGMENTATION BY THERAPIES
  • GLOBAL HEPATITIS THERAPEUTICS MARKET

OTHER CAUSES INCLUDE HEAVY CONSUMPTION OF ALCOHOL, TOXINS, MEDICATIONS, AND OTHER INFECTIONS SUCH AS HIV AND AUTOIMMUNE DISEASES.

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.
  • 3.6 SOVALDI / HARVONI SALES & FORECAST

The Sovaldi/ Harvoni sales was the second biggest drugs sales in the universe just short of the US$ ##. ## Billion in sales recorded in 2014 by AbbVie' s autoimmune disease drug Humira, which is believed to be the world' s topselling pharmaceutical.

  • Hepatitis
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • PERKINELMER

IT IS THE WORLD LEADER IN IN VITRO DIAGNOSTICS AND MEDICINES FOR CANCER AND TRANSPLANTATION; IT IS ALSO ACTIVE IN SEVERAL OTHER MAJOR THERAPEUTIC AREAS INCLUDING AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, VIROLOGY, METABOLIC DISORDERS AND DISEASES OF THE CENTRAL NE

  • Hepatitis
  • China
  • Abbott Laboratories, Inc.
  • Immucor, Inc.
  • Roche Group
  • Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma
  • Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer

Tiziana Life Sciences is developing foralumab for treatments of autoimmune and inflammatory diseases.

  • Hepatitis
  • Pharmaceutical
  • Therapy
  • United Kingdom
  • Tiziana Life Sciences PLC

ORIBASE PHARMA HAS THE CO-PROPERTY AND EXCLUSIVE RIGHT OF EXPLOITATION OF INVENTIONS OF THE ANTIBODIES THAT WILL BE DEVELOPED IN THE FIELD OF DIAGNOSIS AND TREATMENT OF HUMAN CANCERS, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES.

  • Hepatitis
  • Oncology
  • Pharmaceutical
  • Therapy
  • Exelixis, Inc.
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • Johnson & Johnson - Discovery, 2016

Deficiencies in these cells can result in a range of autoimmune diseases.

  • Hepatitis
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States
  • PIPELINE BY NOVARTIS AG, H1 2018

Its drug candidate, PRN##, a reversible covalent BTK inhibitor, is in Phase ## development for pemphigus vulgaris, an orphan autoimmune disease and PRN## is in Phase ## for solid tumors.

  • Cancer
  • Hepatitis
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

The presentation focused on Can-Fite' s CF## for the treatment of autoimmune and anti-inflammatory diseases.

  • Cardiovascular Drug
  • Hepatitis
  • Therapy
  • World
  • Can-Fite BioPharma Ltd.
  • R&D Progress

Reasons for premature withdrawal included patient refusal to continue or withdrew consent (## patients), disease remission (## patient) and death due to an acute infection (## patient).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • REPLICor Inc.
  • OTHER LOCATIONS & SUBSIDIARIES

Tiziana Life Sciences is developing foralumab for treatments of autoimmune and inflammatory diseases.

  • Cancer
  • Hepatitis
  • United Kingdom
  • Deals & Alliance
  • Tiziana Life Sciences PLC

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.
  • R&D Progress

Reasons for premature withdrawal included patient refusal to continue or withdrew consent (## patients), disease remission (## patient) and death due to an acute infection (## patient).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • REPLICor Inc.
  • SWOT Analysis - Overview

The company' s ddRNAi technology holds significant potential to address various disease conditions in the therapeutic domain of cancer (lung, liver, and breast), neurological diseases (huntingdons, dementia, and glioblastoma), infectious diseases (HIV/ AIDS, Hepati

  • Biopharmaceutical
  • Hepatitis
  • RNA Interference
  • Therapy
  • Benitec Biopharma Limited

Results Overall in BRCA positive patients (Parts ## and ##, n=##), disease control rate is ##. ##% and overall response rate (ORR) is ##% (Part ## ORR ##% and Part ## ##%).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.

Overall in BRCA positive patients (Parts ## and ##, n=##), disease control rate is ##. ##% and overall response rate (ORR) is ##% (Part ## ORR ##% and Part ## ##%).

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.

Four CLL patients achieved stable disease (SD).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • Tragara

Monoclonal Antibody for Autoimmune Disease - Drug Profile Monoclonal Antibody for Autoimmune Disease Ono Pharmaceutical Co., Ltd.

  • Hepatitis
  • Lung Cancer
  • Pharmaceutical
  • United States
  • Ono Pharmaceutical Co., Ltd.

It offers products for oncology, cardiovascular and metabolic diseases, respiratory and autoimmune diseases.

  • Hepatitis
  • HIV AIDS
  • United States
  • Company
  • Bristol-Myers Squibb Company
  • SPRING BANK PHARMACEUTICALS INC

NA : Not Available Source: Global Markets Direct RGT-## - DRUG PROFILE and/ or IL-## and/ or IL-##β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies,

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Rigontec GmbH

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Eisai Co., Ltd.

These cells are functional and suppress the development of experimental spontaneous autoimmune diseases.

  • Hepatitis
  • Therapy
  • World
  • Product Initiative
  • Shenogen Pharma Group

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Hepatitis
  • Oncology
  • United States
  • Product Initiative
  • Exelixis, Inc.